ProclaRx, based in Athens OH, is a pre-clinical stage biopharmaceutical company with the exclusive worldwide rights to develop and commercialize our first-in-class anti-bacterial biofilm IP technology. Our labs and regulatory and clinical partners optimize our commercialization pathways while keeping costs low.

ProclaRx pursuit of device (510K) and orphan designations, GAIN ACT and FDA Fast Track designations will move our products to license and/or sale faster than is typical in the drug industry. Wound care leads the way with an expedited 510K approval process launching in 2017. Ear infections and sinusitis will follow with initiation of IND-enabling studies in 2017.


Nick Henderson

Nick Henderson, MBA

Chairman of the Board

Nick Henderson is Managing Partner of Applied Bio Ventures. Prior to that, he was CEO of Applied Biomolecular Technologies, a technology development company focused on commercializing technology. Nick was the founder and President of Signature Medical Direct, which he sold to an industry leader in 2010. He has extensive entrepreneurial experience, having started and grown 14 businesses and one foreign (GmbH) operation. His passion is helping entrepreneurs successfully launch and scale new ventures. He is Chairman of the Board of the Economic Community Development Institute. Nick received his Bachelor of Science degree in Accounting from The Pennsylvania State University and his MBA from The University of Dayton.

Joesph Kittle

Joseph D. Kittle Jr., Ph.D.

Chief Executive Officer

Joseph D. Kittle Jr., Ph.D. has over 20 years of experience in the world of biotechnology. Dr. Kittle has expertise in the development of products and services in the areas of: Genome Engineering; Gene Synthesis; Realtime DNA Analysis; Genomics; as well as Protein Expression and Purification. He has held key positions at CODA Genomics (VP of Research and Technology), and at Lark Technologies (Director of New Products), where he displayed a keen understanding of product development along with a deep knowledge knowledge of chemistry, biochemistry, and synthetic biology. Dr. Kittle received his undergraduate degree in chemistry from Ohio University, then went on to Harvard, where he earned his Ph.D. in Chemistry. After completing his post doc work at Ohio State University in biochemistry in 1991, he worked as a scientist at Battelle for 3 years.

Tom Zupancic

Tom Zupancic, Ph.D.

Chief Scientific Officer

Tom Zupancic, Ph.D. is a molecular biologist with more than 25 years of experience in the design and execution of applied biotechnology research projects. He has extensive hands-on experience designing and leading product development programs in Biotechnology and Biopharmaceutical development. Specific projects span a broad range of scientific and technology areas including: genetic engineering; molecular biology; protein therapeutics; bioproduction processes; bioinformatics; functional genomics; immunology; disease biology and vaccine development. Dr. Zupancic has had a distinguished career in industry, working for GeneticXchange, LabBook, Inc, and the Battelle Memorial Institute in roles ranging from Chief Scientific Officer to Applied Scientist. He holds 17 US patents. Dr. Zupancic has specific expertise in the area of intellectual property development gained as a Senior Scientific Advisor for Intellectual Property with Baker and McKenzie LLP. He graduated cum laude from the Ohio State University, with Distinction in Genetics and Phi Beta Kappa. He received his Ph.D. in Molecular Biology from Indiana University, where he was a National Science Foundation Graduate Fellow.

Rich Brody

Rich Brody, Ph.D., VP

Research and Development

Rich Brody is a biochemist with more than 30 years of experience directing laboratory programs in protein biochemistry. He directed contract research programs at Battelle, where completing projects on time and on budget was essential. Most recently, Dr. Brody has focused his R&D efforts on antibody development and has directed investigations of antibody purification, characterization, modification, and stabilization. Dr. Brody has worked extensively in the biotechnology industry, where he was Director of Protein Research for Progenitor Corporation. He has also worked in academia, where he was an Assistant Professor of Chemistry at the University of Buffalo. His specialties include: Protein Modification (e.g. pegylation, labeling); Protein Purification; Protein Characterization; Protein Stabilization; and Assay Development. Dr. Brody received his undergraduate degree in Chemistry from Cornell University, and received his Ph.D. in Chemistry from Harvard University, where he investigated multiple problems in the mechanisms of enzyme action.

Doug Martin

Doug Martin

Chief Operating Officer

Doug Martin brings more than 20 years of extensive legal and business experience to his new executive role at ProclaRx. As COO, Mr. Martin will be responsible for the strategic planning, compliance, and coordination of R&D resources. He will report directly to Nick Henderson, Chairman of the Board at ProclaRx.